- Home
- CRGX vs ISRL Comparison
CRGX vs ISRL Comparison
Compare CRGX & ISRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- ISRL
- Stock Information
- Founded
- CRGX 2021
- ISRL 2021
- Country
- CRGX United States
- ISRL United States
- Employees
- CRGX N/A
- ISRL N/A
- Industry
- CRGX
- ISRL Blank Checks
- Sector
- CRGX
- ISRL Finance
- Exchange
- CRGX Nasdaq
- ISRL Nasdaq
- Market Cap
- CRGX 180.4M
- ISRL N/A
- IPO Year
- CRGX 2023
- ISRL 2023
- Fundamental
- Price
- CRGX $4.07
- ISRL $11.46
- Analyst Decision
- CRGX Hold
- ISRL
- Analyst Count
- CRGX 7
- ISRL 0
- Target Price
- CRGX $4.67
- ISRL N/A
- AVG Volume (30 Days)
- CRGX 773.9K
- ISRL 1.9K
- Earning Date
- CRGX 03-12-2025
- ISRL 01-01-0001
- Dividend Yield
- CRGX N/A
- ISRL N/A
- EPS Growth
- CRGX N/A
- ISRL N/A
- EPS
- CRGX N/A
- ISRL 0.26
- Revenue
- CRGX N/A
- ISRL N/A
- Revenue This Year
- CRGX $119.08
- ISRL N/A
- Revenue Next Year
- CRGX N/A
- ISRL N/A
- P/E Ratio
- CRGX N/A
- ISRL $43.91
- Revenue Growth
- CRGX N/A
- ISRL N/A
- 52 Week Low
- CRGX $3.00
- ISRL $10.81
- 52 Week High
- CRGX $25.45
- ISRL $11.58
- Technical
- Relative Strength Index (RSI)
- CRGX 40.37
- ISRL 49.41
- Support Level
- CRGX $3.98
- ISRL $11.42
- Resistance Level
- CRGX $4.25
- ISRL $11.50
- Average True Range (ATR)
- CRGX 0.22
- ISRL 0.01
- MACD
- CRGX 0.16
- ISRL -0.00
- Stochastic Oscillator
- CRGX 36.84
- ISRL 50.00
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.